Clinical trial NCT01889147: Microdose and First-In-Human (FIH) Study of Recombinant Human Placental Alkaline Phosphatase (hRESCAP)
Official title: A Single Dose Study to Assess the Peak Plasma Concentration of a Microdose of Recombinant Human Placental Alkaline Phosphatase (hRESCAP, Part 1) Followed by a Single Ascending Dose, FIH Study to Assess Safety and Tolerability of hRESCAP (Part 2).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Healthy
Keywords: Peak plasma concentration
safety and efficacy
therapeutic agent
LPS-mediated diseases
Pharmacokinetics of administered hRESCAP
Determine half-time
Lead sponsor: TNO
Sponsor class: OTHER
Collaborators: name: Alloksys Life Sciences B.V.
First posted: 2013-06-28
Enrollment: 4
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: In the present study human recombinant placental alkaline phosphatase (hRESCAP) will be investigated. Alkaline Phosphatase is naturally present in the body and reported to use lipopolysaccharde (LPS, bacterial endotoxins) and extracellular nucleotides leaking from damaged and ischemic cells as physiological substrates. The LPS-substrate prevalence makes alkaline phosphatase an interesting novel therapeutic agent in the treatment of LPS-mediated diseases. A bovine homologue of this protein (bovine intestinal alkaline phosphatase, BIAP) has previously been investigated for treatment of acute inflammatory responses such as sepsis, and was shown to be safe in humans. hRESCAP, which will be investigated in the current study, is expected to have a longer half-life in humans than the previously investigated BIAP, due to the fact that it is more sialylated. The possibility to increase the t1/2 to days instead of minutes enables treatment of chronic diseases.

Detailed description: In the current study the peak plasma concentration (pharmacokinetics/elimination) of \[14C\]-labelled hRESCAP in healthy volunteers will be investigated at increasing single doses (up to anticipated therapeutic dose), with a microdose (≤30 nmol) as a safe starting dose.

* Part 1: To assess the peak plasma concentration of a single microdose (≤30 nmol) of a recombinant human protein (hRESCAP), administered intravenously, as a suitable technique to predict the pharmacokinetics in humans at pharmacologically relevant doses;
* Part 2: To determine the safety and tolerability of single dose of hRESCAP up to 5300 µg in healthy male volunteers administered intravenously;
* To determine the peak plasma concentration of hRESCAP in healthy male volunteers within a pharmacologically relevant dose-range and compare this with BIAP pharmacokinetics with emphasis on half-life (t1/2).

Eligibility criteria: Inclusion Criteria:

1. Healthy male subjects, 18 - 45 years of age, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, haematology, blood chemistry, and urinalysis;
2. Body mass index (BMI) between 18 and 30 kg/m2, inclusive;
3. Ability to communicate well with the investigator in the Dutch language;
4. Able to participate and willing to give written informed consent and to comply with the study restrictions;
5. Venous access sufficient to allow blood sampling as per protocol.

Exclusion Criteria:

1. Any clinically significant abnormality as determined by medical history taking and physical examinations obtained during the screening visit that in the opinion of the investigator would interfere with the study objectives or compromise subject safety;
2. History of a surgical event that may significantly affect the study outcome;
3. History of allergy or other inflammatory indications;
4. History of asthma or other inflammatory disease;
5. Use of prescription medications, over the counter medications, vitamin, herbal and dietary supplements within 21 days prior to study drug administrations, or less than 5 half-lives, whichever is longer, and during the course of the study.
6. Alkaline Phosphatase levels in plasma of \< 30 IU/L or \> 115 IU/L;
7. Clinically relevant abnormal laboratory results, ECG, vital signs, or physical findings at screening that in the opinion of the investigator would interfere with the study objectives or compromise subject safety;
8. Participation in an investigational drug, food (ingredients) or device study within 3 months prior to screening or more than 4 times in the past year;
9. Any psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol;
10. History of alcohol or illicit drug abuse (alcohol abuse defined as alcohol consumption \> 28 units/week);
11. Reported unexplained weight loss or weight gain of \> 2 kg in the month prior to screening;
12. Positive test results for Hepatitis B, Hepatitis C or HIV;
13. Donation of blood within 3 months prior to screening or donation of plasma within 14 days prior to screening;
14. Not having a general practitioner;
15. Not willing to accept information transfer which concerns participation in the study, or information regarding health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner;
16. Not willing to give permission to have the general practitioner to be notified upon participation in this study;
17. Prior participation in part 1 is not allowed for subjects participating in part 2.

Primary outcomes:
measure: Evaluate the peak plasma concentration of hRESCAP after microdose administration of hRESCAP
timeFrame: 35 days
Secondary outcomes:
measure: In the ascending dose study increased dosages of of hRESCAP will be supplied till finally the therapeutic dose.
timeFrame: Two weeks (based upon time phrame of micodose section of the study)
Other outcomes:
Locations:
city: Leiden
country: Netherlands
facility: Centre for Human Drug Research
state: South-Holland
Study officials:
affiliation: CHDR
name: Koos Burggraaf, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: